Media stories about Catalyst Pharmaceuticals (NASDAQ:CPRX) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.2659725293158 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of analysts recently weighed in on the stock. BidaskClub cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. SunTrust Banks set a $5.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, December 21st. Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Piper Jaffray Companies set a $8.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $6.25.
Shares of Catalyst Pharmaceuticals (CPRX) opened at $3.93 on Friday. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The firm has a market cap of $338.16, a price-to-earnings ratio of -18.71 and a beta of 1.68.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.